Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Works With City of Hope on RNAi-Based Treatment for HIV

NEW YORK, Aug. 25 (GenomeWeb News) - Benitec said today that it will begin sponsoring research at City of Hope's Beckman Research Institute in an attempt to develop an HIV/AIDS drug using Benitec's ddRNAi technology.

 

The research will be based on the work of John Rossi, chair of the division of molecular biology at Beckman.

 

"The experimental treatment we are planning will give patients their own blood stem cells that have been genetically modified using ddRNAi to generate HIV resistance," Rossi said in a statement. "If this engraftment of HIV-resistant stem cells is successful, the new blood cells would be a barrier to continued HIV replication."

 

Benitec said it expects the therapeutic to enter the clinic in 2005, and that this will be the subject of a further agreement with City of Hope.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.